{
    "2021-03-26": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Pfizer (PFE) Gets Unfavorable Votes from FDA Panel for Tanezumab",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "FDA",
                        "Tanezumab",
                        "Unfavorable Votes"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Looking Into Eli Lilly's Return On Capital Employed",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Return On Capital Employed"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Pfizer And Eli Lilly's Osteoarthritis Drug Rejected By FDA Panel As Too Risky",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Eli Lilly",
                        "Osteoarthritis Drug",
                        "FDA Panel",
                        "Rejected",
                        "Too Risky"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}